ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
UTHR
|
Pulmonary Arterial Hypertension
|
Phase 2
|
2017-07-10 00:00:00
|
Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed.
| 0 |
NVS
|
Non-radiographic axial spondyloarthritis
|
Approved
|
2020-06-16 00:00:00
|
FDA Approval announced June 16, 2020.
| 1 |
MRK
|
Hepatocellular carcinoma (HCC)
|
Approved
|
2018-11-09 00:00:00
|
FDA approval announced November 9, 2018.
| 1 |
MRK
|
Renal Cell Carcinoma
|
Approved
|
2021-08-11 00:00:00
|
FDA approval announced August 11, 2021.
| 1 |
PIRS
|
Gastric cancer
|
Phase 1
|
2019-11-09 00:00:00
|
Phase 1 data at SITC November 9, 2019 noted 2/18 response rate.
| 0 |
VBIV
|
Recurrent glioblastoma multiforme (rGBM)
|
Phase 2b
|
2023-09-07 00:00:00
|
Phase 2b treatment in the primary GBM expected to commenced, noted September 7, 2023.
| 1 |
AIM
|
Ovarian cancer
|
Phase 2
|
2022-03-09 00:00:00
|
Phase 2 data reported 2 complete responses, 3 partial responses, 3 stable diseases, 5 progressive diseases and a total clinical benefit rate of 61.6%, noted March 9, 2022.
| 0 |
IXHL
|
Obstructive sleep apnoea (OSA)
|
Phase 2
|
2022-06-03 00:00:00
|
Complete Phase 2 analysis concluded that treatment reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed. The low dose exhibited superior safety and efficacy metrics to mid and high doses. The low dose also reduced AHI by an average of 50.7% compared to baseline with 25% of participants experiencing a reduction in the apnoea hypopnea index of greater that 80%.
| 1 |
SNY
|
Asthma - 6-11 year-olds
|
Approved
|
2021-10-20 00:00:00
|
Approved October 20, 2021.
| 1 |
EXEL
|
First-Line RCC - cancer
|
Approved
|
2017-12-19 00:00:00
|
Approval announced December 19, 2017, ahead of PDUFA date of February 15, 2018.
| 1 |
ALGS
|
HBeAg-positive chronic hepatitis B (CHB)
|
Phase 1b
|
2023-06-21 00:00:00
|
Additional Phase 1b data presented at EASL demonstrated multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks, noted June 21, 2023.
| 1 |
BXRX
|
Neuromuscular blockade (NMB) in patients undergoing elective surgery
|
Phase 2
|
2023-06-07 00:00:00
|
hase 2 primary efficacy endpoint was the proportion of patients that met criteria for Good or Excellent intubating conditions using a standardized scale. All patients, across regimens, met the primary efficacy criteria, noted June 7, 2023.
| 0 |
AZN
|
Venous thromboembolism (VTE) Prevention
|
Approved
|
2017-06-23 00:00:00
|
FDA Approval noted June 23, 2017.
| 1 |
SPRO
|
Nontuberculous mycobacterial (NTM) pulmonary disease (PD)
|
Phase 2
|
2021-02-05 00:00:00
|
Phase 2a trial placed on clinical hold - February 5, 2021.
| 0 |
AMGN
|
Oral corticosteroid dependent asthma.
|
Phase 3
|
2020-12-22 00:00:00
|
Phase 3 trial did not meet primary endpoint - December 22, 2020.
| 1 |
ZLAB
|
Non-Hodgkin Lymphoma (NHL)
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 data presented at ASH showed a 49% ORR in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR), noted December 12, 2022.
| 1 |
COCP
|
Influenza
|
Phase 1
|
2023-05-04 00:00:00
|
Phase 1 data reported no serious AEs, treatment discontinuations, and no clinically significant observations noted in laboratory assessments, vital signs, physical exam findings, or ECGs, noted May 4, 2023.
| 1 |
LGND
|
Pneumococcal Conjugate Vaccine
|
Phase 3
|
2023-07-27 00:00:00
|
Phase 3 trial met primary endpoints, noted July 27, 2023.
| 0 |
MRK
|
Endometrial cancer
|
Approved
|
2019-09-17 00:00:00
|
FDA Approval announced September 17, 2019.
| 1 |
SRPT
|
Duchenne muscular dystrophy
|
Phase 3
|
2022-10-14 00:00:00
|
Phase 3 results presented at the World Muscle Society reported that mean dystrophin levels significantly increased from baseline after 48 weeks of casimersen treatment, noted October 14, 2022.
| 1 |
THRX
|
Gastrointestinal stromal tumors (GIST)
|
Phase 1/2
|
2023-05-25 00:00:00
|
Phase 1/2 dose-escalation data demonstrated encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation, noted May 25, 2023.
| 1 |
VIGL
|
Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
|
Phase 1
|
2022-12-14 00:00:00
|
Phase 1 trial achieved favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohorts. VGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action, noted December 14, 2022.
| 1 |
BMY
|
Gastric cancer
|
Approved
|
2021-04-16 00:00:00
|
FDA approval announced April 16, 2021.
| 1 |
PFE
|
ALK-positive Anaplastic Large Cell Lymphoma
|
Approved
|
2021-01-14 00:00:00
|
FDA approval announced January 14, 2021.
| 1 |
XAIR
|
Solid tumors
|
Phase 1
|
2023-11-03 00:00:00
|
Phase 1 data presented at SITC demonstrated early clinical proof of concept, noted November 3, 2023.
| 1 |
VERU
|
ER+/HER2- breast cancer
|
Phase 3
|
2023-09-11 00:00:00
|
Phase 3 enrollment discontinued due to prioritization with Phase 3 data overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated population versus no responses in the standard of care active control arm. Overall response rate was 20% for enobosarm monotherapy versus 0% for standard of care active control in patients who had ≤3 lines of prior endocrine therapy in the metastatic setting, noted September 11, 2023. ARTEST clinical data further validates the evaluation of enobosarm in the Phase 3 ENABLAR-2 study.
| 1 |
TRVI
|
Chronic cough - Idiopathic pulmonary fibrosis (IPF)
|
Phase 2
|
2022-09-19 00:00:00
|
Phase 2 full data reported that trial met primary endpoint, noted September 19, 2022.
| 0 |
GOSS
|
Nasal polyps / chronic rhinosinusitis
|
Phase 2
|
2020-10-13 00:00:00
|
Phase 2 trial did not meet primary endpoint - October 13, 2020.
| 1 |
AZN
|
Severe, uncontrolled asthma
|
Phase 3
|
2017-05-10 00:00:00
|
Phase 3 trial did not meet primary endpoint - May 10, 2017.
| 1 |
ATNF
|
Dupuytren’s disease (DD)
|
Phase 2/3
|
2021-12-01 00:00:00
|
Phase 2b data from 2b/3 trial reported that trial met its primary and secondary endpoint with no related severe adverse events, noted December 1, 2021.
| 0 |
ASND
|
Growth Hormone Deficiency - adults
|
Phase 3
|
2023-09-23 00:00:00
|
Phase 3 resultspresented at ESPE 2023 showed that the majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit, noted September 23, 2023.
| 1 |
ADAP
|
Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)
|
Phase 1
|
2022-05-26 00:00:00
|
Phase 1 data released May 26, 2022. The overall response rate was 36% in heavily pre-treated patients across both types of sarcomas (41% in synovial sarcoma and 10% for MRCLS), with a median duration of response of 52 weeks. As reported last year, the pivotal trial SPEARHEAD-1 met its primary endpoint for efficacy and the benefit:risk profile of afami-cel has been favorable with mainly low-grade cytokine release syndrome and tolerable/reversible hematologic toxicities.
| 1 |
PFE
|
Early stage breast cancer
|
Phase 3
|
2020-10-09 00:00:00
|
Phase 3 trial did not meet primary endpoint - October 9, 2020.
| 1 |
PDSB
|
Human papillomavirus (HPV) associated cancers
|
Phase 2
|
2022-12-28 00:00:00
|
Phase 2 data reported a median OS of 21 months, with 75% remain alive at a median follow-up of 27 months, noted December 28, 2022.
| 0 |
VTVT
|
Type 2 Diabetes
|
Phase 2
|
2016-12-14 00:00:00
|
Phase 2 primary endpoint met - December 14, 2016.
| 0 |
NKTR
|
Solid tumors
|
Phase 1/2
|
2019-03-01 00:00:00
|
Phase 1/2 initial data March 1, 2019 noted ORR 2/11 ( 18%) - maximum tolerated dose has not been reached.
| 1 |
RHHBY
|
Follicular lymphoma
|
Phase 3
|
2022-06-10 00:00:00
|
Phase 3 final analysis reported that PFS was significantly improved with Gazyva plus chemotherapy (63.4%) compared with Rituxan plus chemotherapy (55.7%), noted June 10, 2022.
| 1 |
RANI
|
Rheumatoid arthritis
|
Phase 1
|
2023-11-01 00:00:00
|
Program paused, noted November 1, 2023.
| -1 |
IPSEY
|
Castration-Resistant Prostate Cancer
|
Phase 3
|
2023-08-21 00:00:00
|
Phase 3 data reported that the trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival (PFS) at the primary analysis, noted August 21, 2023.
| 1 |
EYPT
|
Diabetic macular edema
|
Approved
|
2014-09-26 00:00:00
|
Approved Sept 26 2014.
| 1 |
KMDA
|
AATD - Alpha-1 Antitrypsin deficiency
|
Phase 2
|
2016-08-30 00:00:00
|
Top-line data released August 30, 2016. Primary endpoint met
| 0 |
FRTX
|
Axillary hyperhidrosis
|
Phase 3
|
2021-10-07 00:00:00
|
Phase 3 study demonstrated that dosing was generally well-tolerated, the proportion of subjects achieving at least a 2-point improvement in the HDSM-Ax1 score from baseline to EOT2 was 49.3% (n=173). Additionally the change in GSP3 from baseline to EOT was -129.5mg. Overall, 82% of patients who were randomized to the dose in the study completed the full six weeks of treatment. Five (2.9%) subjects who received the dose discontinued due to a TEAE. No treatment-related Serious Adverse Events (SAEs) were reported. Noted October 7, 2021.
| 1 |
BPMC
|
PDGFRA exon 18 mutant Gastrointestinal stromal tumors (GIST)
|
Approved
|
2020-01-09 00:00:00
|
FDA Approval announced January 9, 2020.
| 1 |
IPHA
|
Hematological malignancies
|
Phase 1/2
|
2023-10-16 00:00:00
|
Phase 1/2 data from ESMO abstract reported that 3/8 patients achieved complete remission (CR), noted October 16, 2023.
| 1 |
SGMO
|
Fabry disease
|
Phase 1/2
|
2023-05-22 00:00:00
|
FDA fast-track designation granted on May 22, 2023.
| 0 |
APLIF
|
Parasitic and anaerobic bacterial infections
|
Approved
|
2023-09-25 00:00:00
|
Approved September 25, 2023.
| 1 |
RHHBY
|
Third-line advanced or metastatic colorectal cancer
|
Phase 3
|
2018-05-10 00:00:00
|
Phase 3 data released May 10, 2018. Primary endpoint not met.
| 0 |
BMY
|
Lupus Erythematosus (SLE)
|
Phase 2
|
2021-11-08 00:00:00
|
Phase 2 52-week data reported that the primary endpoint, SRI-4 response at wk 24, was achieved by 54.3% of patients on iberdomide 0.45 mg vs. 34.9% on placebo, noted November 8, 2021.
| 1 |
FDMT
|
Fabry Disease
|
Phase 1/2
|
2023-10-30 00:00:00
|
Phase 1/2 FDA meeting to lift clinical hold and continue trial developments, noted October 30, 2023.
| 1 |
AMAM
|
HER2-positive metastatic breast cancer
|
Phase 3
|
2023-03-01 00:00:00
|
Phase 3 trial met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater progression-free survival benefit compared to the control, noted March 1, 2023.
| 1 |
NVS
|
Inoperable progressive midgut NETs
|
Approved
|
2018-01-26 00:00:00
|
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
| 1 |
JAGX
|
Chemotherapy-induced diarrhea (CID) in dogs
|
Approved
|
2021-12-21 00:00:00
|
FDA conditionally approved on December 21, 2021.
| 1 |
NKTR
|
Solid tumors
|
Phase 1/2
|
2021-11-12 00:00:00
|
Phase 1b data from 1b/2 trial reported 1 partial response (PR) and 5 stable disease (SD). Treatment was noted to be well tolerated, November 12, 2021.
| 1 |
FREQ
|
Acquired Sensorineural Hearing Loss (SNHL)
|
Phase 2b
|
2023-02-13 00:00:00
|
Phase 2b study failed to achieve its primary efficacy endpoint of an improvement in speech perception. The Company will now discontinue the FX-322 development program, noted February 13, 2023.
| 1 |
ERYP
|
Acute lymphoblastic leukemia (ALL)
|
Phase 2
|
2020-12-06 00:00:00
|
Phase 2 data presented at ASH December 6, 2020. Endpoints met.
| 1 |
ABBV
|
Upper Limb Spasticity
|
Approved
|
2021-07-29 00:00:00
|
FDA approval announced July 29, 2021.
| 1 |
ITCI
|
Bipolar depression
|
Phase 3
|
2019-07-08 00:00:00
|
Phase 3 trial met primary endpoint - July 8, 2019.
| 0 |
RHHBY
|
COVID-19 (Anti-viral antibody)
|
Phase 2/3
|
2021-09-30 00:00:00
|
Phase 3 trial met primary endpoint, with 36% reduced risk of death by day 29, and 56% reduced risk in patients who were seronegative. Of 2,007 patients (REGEN-COV=1,340, placebo=667) serious adverse events occurred in 21% REGEN-COV patients and 26% placebo patients, noted September 30, 2021.
| 1 |
MRK
|
Colorectal cancer (CRC)
|
Approved
|
2020-06-29 00:00:00
|
FDA Approval announced June 29, 2020.
| 1 |
BMRN
|
Hemophilia A
|
Approved
|
2023-06-29 00:00:00
|
Approved June 29, 2023.
| 1 |
BBIO
|
ATTR-PN
|
Phase 3
|
2022-02-28 00:00:00
|
Phase 3 trial has been initiated. Phase 3 trial has been withdrawn, noted February 2022.
| 0 |
PFE
|
Tick-borne encephalitis (TBE) vaccine
|
Approved
|
2021-08-13 00:00:00
|
FDA Approval announced August 13, 2021
| 1 |
PFE
|
COVID-19 Vaccine (Booster)
|
Phase 1/2
|
2022-05-23 00:00:00
|
Phase 1/2/3 booster trial in children reported that a 80.3% vaccine efficacy, noted May 23, 2022.
| 0 |
SNY
|
Coronavirus COVID-19
|
Phase 3
|
2020-09-01 00:00:00
|
Phase 3 global trial did not meet primary endpoint - September 1, 2020.
| 1 |
MRK
|
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
|
Approved
|
2017-05-10 00:00:00
|
Approved May 10, 2017.
| 1 |
ALEC
|
Alzheimer’s disease
|
Phase 2
|
2023-09-07 00:00:00
|
Phase 2 enrollment to be completed, noted September 7, 2023.
| 0 |
DRRX
|
Alcoholic hepatitis (AH)
|
Phase 2b
|
2023-09-07 00:00:00
|
Phase 2b last patient dosed, noted September 7, 2023
| 0 |
ZLAB
|
Chronic inflammatory demyelinating polyneuropathy (CIDP)
|
Phase 2
|
2023-07-17 00:00:00
|
Phase 2 trial met primary endpoints, noted July 17, 2023.
| 0 |
MRK
|
HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinoma
|
Phase 3
|
2023-10-20 00:00:00
|
Phase 3 trial data presented at ESMO demonstrated a statistically significant PFS improvement in advanced HER2-positive gastric or GEJ adenocarcinoma in tumors expressing PD-L1 (Combined Positive Score [CPS] ≥1) compared to trastuzumab and chemotherapy alone October 20, 2023.
| 1 |
NVS
|
Alzheimer’s Disease
|
Phase 2/3
|
2019-07-11 00:00:00
|
Phase 2/3 trial discontinued due to lack of efficacy.
| -1 |
CVAC
|
Covid-19 vaccine, omicron variant
|
Phase 1
|
2023-01-30 00:00:00
|
Phase 1 immunogenicity data reported that on day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against BA.1 of 13.3, noted January 30, 2023.
| 0 |
ZLAB
|
Solid tumors
|
Phase 1
|
2021-10-07 00:00:00
|
Phase 1 updated data noted a confirmed responses for a cORR of 36% out of the 11 MET TKI-naïve NSCLC patients, cORR of 33% for the nine MET TKI-naïve GC/GEJ patients, and among the 12 patients with advanced other solid tumors, one patient with MET amplified colorectal cancer achieved a confirmed response, noted October 7, 2021.
| 1 |
LXRX
|
Diabetic Peripheral Neuropathy
|
Phase 2
|
2022-11-14 00:00:00
|
Phase 2 final results reported no evidence of withdrawal symptoms or rebound pain after treatment ended, noted November 14, 2022.
| 1 |
NVS
|
HR+/HER2- advanced breast cancer
|
Approved
|
2017-03-13 00:00:00
|
Priority review granted November 1, 2016. Approval announced March 13, 2017.
| 1 |
ABBV
|
Relapsed or refractory MCL mantle cell lymphoma
|
Approved
|
2013-11-13 00:00:00
|
Approved November 13, 2013.
| 1 |
IBRX
|
BCG-Unresponsive Bladder Cancer Carcinoma
|
BLA Filing
|
2023-10-23 00:00:00
|
BLA Resubmitted to the FDA, noted October 23, 2023.
| 0 |
BHC
|
Acne
|
Approved
|
2018-08-24 00:00:00
|
FDA Approval announced August 24, 2018.
| 1 |
LNTH
|
Prostate cancer
|
Approved
|
2021-05-27 00:00:00
|
FDA Approval announced May 27, 2021.
| 1 |
MITO
|
Barth syndrome
|
NDA Filing
|
2021-10-20 00:00:00
|
Refusal to File letter from FDA on October 20, 2021, due to issues with Phase 2 trial and open label extension.
| 0 |
ATHA
|
Mild-to-moderate Alzheimer's disease
|
Phase 2
|
2023-04-25 00:00:00
|
Phase 2 statistically significant decrease in plasma NfL levels compared with placebo, noted April 25, 2023.
| 0 |
FDMT
|
Wet age-related macular degeneration (AMD)
|
Phase 1/2
|
2023-07-29 00:00:00
|
Phase 1/2 additional dose response data demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable patients injection-free) and a clinically meaningful reduction in central subfield thickness (CST) at 36 weeks in patient population with high anti-VEGF need, noted July 29, 2023.
| 1 |
BMY
|
Melanoma
|
Phase 2/3
|
2023-10-22 00:00:00
|
Phase 2/3 data presented at ESMO reported that response to NIVO+RELA was associated with increased LAG-3+ CD4+ T cells at week 4, but on-treatment modulation of peripheral CD8+ T cells was not associated with NIVO+RELA efficacy, noted October 22, 2023.
| 1 |
INFI
|
Urothelial cancer
|
Phase 2
|
2022-08-09 00:00:00
|
Phase 2 data reported that 45% of patients were alive compared to only 24% in the control arm, noted August 9, 2022.
| 0 |
AMGN
|
Herceptin biosimilar
|
Approved
|
2019-06-13 00:00:00
|
FDA approval announced June 13, 2019.
| 1 |
MRK
|
HIV-1
|
Phase 2b
|
2021-10-27 00:00:00
|
Phase 2b data through 144 weeks demonstrated that dosing continued to maintain viral suppression, as measured by the number of study participants achieving HIV-1 RNA levels <50 copies/mL, similar to DOR/3TC/TDF, noted October 27, 2021.
| 1 |
BTAI
|
Adjunctive Treatment for Major Depressive Disorder (MDD) for At-Home Use
|
Phase 1b
|
2023-05-16 00:00:00
|
Phase 1b data topline data showed that BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically, noted May 16, 2023.
| 1 |
SNY
|
Influenza A - children 6-35 months of age.
|
Approved
|
2019-11-04 00:00:00
|
sNDA FDA Approval announced for adults over 65 years of age.
| 1 |
IRWD
|
Irritable Bowel Syndrome
|
Phase 2
|
2020-05-27 00:00:00
|
Phase 2 trial did not meet primary endpoint - May 27, 2020.
| 1 |
KMDA
|
COVID-19
|
Phase 1/2
|
2021-03-31 00:00:00
|
Phase 1/2 top-line data released March 31, 2020. 11/12 patients recovered.
| 0 |
MDNA
|
Solid tumors
|
Phase 1/2
|
2023-08-09 00:00:00
|
Phase 1/2 sixth dose escalation cohort data and agent expansion data to showed durable anti-cancer activity observed during monotherapy dose escalation without dose-limiting toxicities. Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11, noted August 9, 2023.
| 1 |
RZLT
|
Congenital hyperinsulinism (HI)
|
Phase 2b
|
2022-03-23 00:00:00
|
Phase 2b study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability, noted March 23, 2022.
| 1 |
AZN
|
COVID-19
|
Phase 3
|
2021-11-18 00:00:00
|
Phase 3 separate treatment trial showed an 88% reduced risk of severe COVID-19 or death when treated within three days of symptom onset.
| 1 |
GRTS
|
Non-small cell lung cancer (NSCLC)
|
Phase 2
|
2022-09-12 00:00:00
|
Phase 2 data presented at ESMO demonstrated early evidence of efficacy with a 39% molecular response rate in evaluable patients, noted September 12, 2022.
| 1 |
LLY
|
Psoriatic Arthritis
|
Phase 3
|
2018-12-17 00:00:00
|
Phase 3 trial met primary and key secondary endpoints.
| 0 |
SRPT
|
Duchenne muscular dystrophy
|
Phase 2
|
2022-07-06 00:00:00
|
Additional data reported that treated patients improved 3.1 points (unadjusted means) and 2.3 points (least squared means) in NSAA total scores from baseline, noted July 6, 2022.
| 1 |
LLY
|
Advanced solid tumors
|
Phase 1b
|
2023-04-18 00:00:00
|
Phase 1b data presented at AACR showed that dosing was well-tolerated with favorable pharmacokinetics and no apparent drug-drug interactions, noted April 18, 2023.
| 1 |
SCYX
|
Recurrent Vulvovaginal candidiasis (rVVC), Vaginal yeast infections
|
Approved
|
2022-12-01 00:00:00
|
FDA Approved on December 1, 2022.
| 1 |
DCPH
|
Gastrointestinal stromal tumor (GIST)
|
Phase 1/2
|
2021-11-30 00:00:00
|
Phase 1b/2 trial discontinued, noted November 30, 2021.
| -1 |
KURA
|
Relapsed or refractory peripheral T-cell lymphoma
|
Phase 2
|
2021-12-13 00:00:00
|
Phase 2 final results reported an overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, noted December 13, 2021.
| 0 |
ANIK
|
Osteoarthritis of the knee
|
Phase 3
|
2022-11-01 00:00:00
|
Third Phase 3 trial met primary endpoint, noted November 1, 2022.
| 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.